Navigating the Perilous Road: A Special Panel On Regulatory and Reimbursement Issues
A panel at OneMedForum NY 2011 will explore strategic planning considerations in the process of getting approval and reimbursement.
Articles by Herina Ayot
June 23-24 OneMedForum New York
OneMedPlace Trans-Atlantic Conference on June 23rd-24th is a gathering of fast growing, emerging healthcare and life science companies in Europe and North America. Its sixth […]
Rib-X Pharmaceuticals’ Nobel Prize Winning Platform Combats Serious Infections
The antibiotic market is expected to reach $45 billion by 2012 driven by the deficiencies of currently available antibiotics.
Small Bone Innovations Addresses Unmet Needs in Joint Replacement
Orthopedic companies have focused on developing devices for large bone trauma, leaving the small bone and joint field lacking.
June 22-23 2011 Wells Fargo Securities Healthcare Conference
Description: Explore the trends driving business in the Biotechnology, Health Care Facilities, Managed Care, Medical, Technology/Devices, Pharma Services, and Pharmaceuticals sectors. For additional details, please […]
Hepregen Awarded $500,000 Massachusetts Life Sciences Center Grant
Hepregen, a leading provider of bioengineered solutions that increase success in drug development, was awarded a $500,000 grant as part of the Small Business Matching Grants program
Phytoceuticals Heals Wounds Through An Easy To Use Spray
This is a new solution that is poised to become the standard of care in wound management because of effective speed, ease of use and cost savings.
Advanced Cardiac Therapeutics Studies Innovative Catheter System To Treat Arrythmias
ACT recently announced that the first patients have been enrolled in a CE Mark clinical trial of the safety and performance of the company’s TEMPASURE cardiac ablation catheter.
InSite Vision Is Developing Treatment For Common Eye Disease Blepharitis, For Which There Is Currently No Approved Treatment
InSite Vision has reached an agreement with the FDA on a Special Protocol Assessment for the design of a Phase 3 clinical trial of treatment in patients with blepharitis.